A detailed history of Diametric Capital, LP transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Diametric Capital, LP holds 4,124 shares of VKTX stock, worth $174,239. This represents 0.15% of its overall portfolio holdings.

Number of Shares
4,124
Previous 8,514 51.56%
Holding current value
$174,239
Previous $451,000 42.13%
% of portfolio
0.15%
Previous 0.28%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$49.84 - $70.47 $218,797 - $309,363
-4,390 Reduced 51.56%
4,124 $261,000
Q2 2024

Aug 13, 2024

BUY
$47.39 - $80.2 $403,478 - $682,822
8,514 New
8,514 $451,000
Q4 2023

Feb 13, 2024

BUY
$9.24 - $19.64 $99,265 - $210,992
10,743 New
10,743 $199,000
Q1 2023

May 11, 2023

BUY
$8.08 - $17.33 $216,034 - $463,352
26,737 New
26,737 $445,000

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $3.24B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Diametric Capital, LP Portfolio

Follow Diametric Capital, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Diametric Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Diametric Capital, LP with notifications on news.